AI analysis of coronary CT scans for personalized heart disease management
Heartflow is an AI-based analysis platform for coronary computed tomography angiography (CCTA) imaging.
AI Panel Score
6 AI reviews
Reviewed
AI Editor ApprovedApproved and published by our AI Editor-in-Chief after full panel analysis.Heartflow works by taking a patient's coronary CT angiography (CCTA) scan and converting it into a dynamic 3D model of the heart. This model gives clinicians a way to assess both the anatomy of the coronary arteries and the physiology of blood flow, rather than relying solely on conventional tests such as stress EKG, stress echo, PET, calcium score, SPECT, or invasive catheterization, which the company states can produce false negatives and false positives that lead to missed diagnoses or unnecessary procedures.
The platform, marketed as Heartflow One, brings together Roadmap, FFRct and Plaque analysis with Plaque Staging, which stages Total Plaque Volume (TPV), and the PCI Navigator pre-planning tool. Roadmap analysis is used to read CCTA scans for early detection of coronary artery disease with consistent results across different readers. FFRct analysis evaluates blood flow at any point in the coronary tree to help determine whether a patient would benefit from revascularization. Plaque analysis quantifies and characterizes plaque buildup to inform risk assessment and ongoing disease management. Heartflow also provides clinical, operational, technical, and financial support to help institutions build and scale CCTA-based cardiology programs.
Heartflow is designed for use by cardiologists, radiologists, and other clinicians involved in diagnosing and managing coronary artery disease, as well as the hospitals and imaging centers that operate CCTA programs. The company reports the platform has been used to treat more than 650,000 patients across over 1,800 institutions, with coverage cited under 99.5% of US health insurance lives. Pricing is not publicly listed and is handled through direct contact with the company; competitors in AI-based cardiac imaging analysis include Cleerly and Elucid.
Heartflow's analysis is derived from standard coronary CTA imaging data, meaning it integrates into existing CT scanning workflows at partner institutions rather than requiring new imaging hardware. The platform is used by clinical staff through a web-based interface for reviewing scan results and 3D models, with optional PACS and EMR delivery; the company cites over 625 peer-reviewed publications related to its technology and clinical validation.
Uses advanced artificial intelligence to securely review patient CT images and generate computer models of coronary anatomy.
An AI-powered, interactive tool that quantifies coronary plaque by type and volume alongside physiology to help clinicians assess a patient's cardiovascular risk.
An AI-enabled product that assists CT readers in identifying the location and severity of coronary artery narrowings (stenoses) accurately and consistently.
Backed by substantial clinical evidence with more than 625 peer-reviewed publications demonstrating outcomes such as reduced unnecessary angiograms and lower cost of care.
Provides quantitative measurement of plaque volume and type to help clinicians more accurately assess patient risk and develop targeted treatment plans.
Builds a highly detailed, personalized digital 3D model of a patient's coronary arteries from CT images to visualize structure and simulate blood flow.
Computes fractional flow reserve (FFRCT), a mathematically derived quantity from simulated pressure, velocity and blood flow, from a 3D model built off static coronary CT images to support functional evaluation of coronary artery disease.
Enables earlier detection of coronary artery disease from CT images without requiring invasive intervention or incurring adverse events associated with angiography.
A unified platform combining FFRCT, Plaque Analysis, Plaque Staging, Roadmap Analysis and PCI Navigator so care teams can explore, evaluate and manage a patient's coronary health in one place.
Offers a dedicated mobile app (available on the App Store) that lets physicians access HeartFlow Analysis results.
Patient CT scan images are securely transmitted and reviewed through HeartFlow's cloud-based analysis pipeline to generate diagnostic results.
Supported by CMS-approved reimbursement in the US and recommended by NICE, with coverage giving over 235 million US patients access to the HeartFlow Analysis through their health insurance.
Heartflow does not publish a list price. The Heartflow One platform is sold directly to hospitals, imaging centers and health systems, with pricing by quote through Heartflow's contact form. The dollar figures Heartflow does publish are CY2026 Medicare reimbursement rates paid to providers for CCTA, FFRCT Analysis and Plaque Analysis (hospital outpatient: $356, $877 and $950), not Heartflow's own fee.
650,000 patients treated, 1,800 institutions live, and CMS pays for it. That's traction, not a pilot.
“HeartFlow has the clinical evidence and insurance coverage most health tech vendors spend a decade chasing. The open question is whether a hospital board sees this as standard of care or a nice-to-have.”
625 peer-reviewed publications. 99.5% of US insurance lives covered. 1,800 institutions already running it. That's not early-stage evidence, that's category infrastructure.
Two things stand out. One: this doesn't replace hardware, it reads CCTA scans clinicians already order, so integration risk is low. Two: FFRCT and Plaque Analysis are backed by ACC/AHA guideline language, which is about as strong as clinical validation gets in cardiology.
The tradeoff: no public pricing, so every deal is a negotiation and budgeting is a black box until legal gets involved. Cleerly and Elucid compete here, but neither has HeartFlow's scan volume or reimbursement footprint. For a hospital cardiology program, this looks less like buying software and more like joining the standard of care.
Ahead of named competitors Cleerly and Elucid on scan volume and insurance coverage breadth.
ACC/AHA-backed validation and CMS reimbursement make this a safe, defensible clinical choice.
No free trial and contract-based pricing mean a slower procurement cycle despite fast clinical payoff once live.
Improves diagnostic accuracy on existing CCTA workflows rather than just cutting cost on current tests.
1,800 institutions and 650,000 patients treated signals durable scale, not a startup burning runway.
Hospitals and imaging centers running or scaling CCTA-based cardiology programs.
Skip it if your CT volume doesn't justify negotiating a per-institution contract.
A validated, guideline-supported CCTA analytics platform that changes how my cath lab decides who goes to the table.
“HeartFlow's FFRct and Plaque Analysis modules give me physiology and anatomy from a single non-invasive scan, backed by over 625 publications. The clinical case is strong; the governance and workflow integration questions are the ones I still have to own.”
625-plus peer-reviewed publications and CMS reimbursement coverage across 99.5% of US insurance lives is not a startup's evidence base — that's the kind of validation depth I need before I put an AI tool between a CCTA scan and a revascularization decision. Roadmap, FFRct, and Plaque Analysis as one unified platform means my cardiologists and radiologists aren't juggling three vendor logins, which matters for adoption at the 1,800-institution scale HeartFlow already claims.
The three-year question is workflow lock-in versus clinical benefit. If we build our chest-pain pathway around HeartFlow One, we reduce unnecessary invasive angiograms — a real outcome — but we also tie our CCTA program's operational and financial support model to one vendor, with pricing negotiated privately rather than benchmarked against Cleerly or Elucid.
No public pricing means every CFO conversation starts from zero leverage. That's my main reservation, not the science.
Leads the CCTA-analytics category ahead of Cleerly and Elucid on both scale (650,000+ patients treated) and guideline citation.
Roadmap, FFRct, and Plaque Analysis map directly onto how cardiologists actually sequence detection, functional assessment, and risk management.
Runs on existing CCTA hardware and adds a web interface plus mobile app, avoiding new capital equipment spend.
Reduces unnecessary angiograms per company claims, but three-year commitment ties institutional workflow and reimbursement strategy to one vendor.
625+ peer-reviewed publications and AHA 2025 data position this as the deepest validated framework in coronary risk stratification I've seen.
Hospitals and imaging centers running CCTA-based cardiology programs that want guideline-backed, non-invasive coronary risk stratification.
Avoid if your institution needs transparent, comparable list pricing before committing budget to a coronary imaging analytics vendor.
Zero list prices published. 1,800 institutions bought anyway — through procurement, not a pricing page.
“No list price, no tiers, no self-serve anything. This is enterprise medtech procurement, priced per contract, per volume, per payer mix.”
No pricing page. I couldn't find a pricing page anywhere. Everything routes through sales. That's category norm for hospital-grade AI diagnostics, but it means TCO modeling starts blind.
What's public: CMS reimbursement rates for CCTA, FFRct and Plaque Analysis services. That's provider revenue, not Heartflow's fee. Two different numbers, easy to confuse in a budget meeting. Coverage under 99.5% of US insurance lives matters for adoption, not for what the hospital pays Heartflow per scan or per year.
Competitors Cleerly and Elucid face the same opacity — this whole category negotiates per institution. 625+ peer-reviewed publications support clinical ROI. Financial ROI is a different question: per-analysis fee, subscription tier, volume discounts — none of it visible pre-contract. Procurement will need a signed NDA before seeing real numbers. Budget accordingly, and expect a multi-month sales cycle before your first invoice.
650,000 patients across 1,800 institutions proves procurement works at scale, but onboarding is sales-led, not self-serve.
No public terms; institutional medtech contracts typically run multi-year with negotiated exit clauses.
No pricing page, no tiers, contact-sales only — none that I could find.
625+ peer-reviewed publications and cited reductions in unnecessary angiograms give a real clinical outcomes trail.
Per-analysis or subscription cost unknown; CMS reimbursement figures don't reveal Heartflow's actual fee.
Hospital systems with existing CCTA programs and a procurement team built for multi-year medtech contracts.
You need a comparable dollar figure before your first sales call.
Solid CCTA read-out tool for the cath lab conference, but the CT tech's workflow still has friction points
“HeartFlow slots FFRct and Plaque Analysis into existing CCTA workflows without new hardware, which matters for adoption. Reimbursement coverage is real, but day-to-day fit for the reading radiologist and referring cardiologist is uneven.”
Roadmap, FFRct, and Plaque Analysis in one platform means I'm not toggling between three vendor logins during a coronary work-up — that's a real win over stitching together calcium score, stress echo, and invasive cath data by hand. The web interface for reviewing 3D models is where clinicians actually spend time, and 625 peer-reviewed publications gives me something to cite in tumor-board-style conferences without digging.
Turnaround is quoted at a 90-minute median from CCTA scan to an FFRct-guided pathway, and results can land directly in PACS and the EMR, with Roadmap arriving as a PDF in PACS — that's the daily detail that decides whether this becomes routine or gets skipped on busy clinic days. Coverage under 99.5% of US insurance lives removes the prior-auth fight, a genuine advantage over Cleerly on the reimbursement front.
No public pricing, no self-serve trial — every institution negotiates blind, which slows adoption at smaller imaging centers weighing this against Elucid.
Web-based 3D model review fits existing CCTA reading sessions without new imaging hardware, per the integration description.
CCTA acquisition guides, a Plaque Analysis clinical guide, education videos and an Insights blog serve practitioners, though I couldn't find a changelog.
A 90-minute median FFRct turnaround and optional PACS/EMR delivery put results where referring clinicians already look.
Plaque Analysis quantifies by type and volume for risk stratification, validated by AHA 2025 data cited in buyer Q&A.
Combines Roadmap, FFRct, and Plaque Analysis into one platform (HeartFlow One) rather than requiring three separate logins.
Cardiology and radiology teams running active CCTA programs who want anatomy and physiology in one read.
You're a smaller imaging center needing transparent pricing before committing budget.
Not a consumer app, but the workflow fit for a cardiologist looks genuinely thought through.
“Heartflow isn't something you sign up for on a whim, it's a hospital-level decision. But the pieces that matter daily, the 3D model, the FFRct numbers, the plaque breakdown, sound like they were built by people who sat in a reading room.”
I can't tell you what the login screen feels like, there's no free trial and no pricing page, this is a call-your-sales-rep product, like Cleerly or Elucid. That's normal for hospital software, but it also means the first ten minutes isn't onboarding, it's a procurement conversation. Public material is clinical, indications for use, CCTA acquisition guides, on-demand education videos, but I couldn't find a changelog.
What I can judge is the workflow logic, and it's solid. Roadmap, FFRct, and Plaque Analysis under one Heartflow One umbrella means a cardiologist isn't tab-switching between three different vendor tools mid-consult. It plugs into existing CCTA scans, no new hardware, which is the kind of integration decision that saves everyone a headache three months in.
The mobile app for physicians reviewing results on the go is a nice touch, though the description reads more like results-viewing than full workflow. With 650,000 patients treated across 1,800 institutions and 99.5% insurance coverage, the scale is real. The tradeoff: you're trusting an algorithm's read on plaque and flow, backed by 625+ studies, but still a black box to the patient on the table.
The Plaque Analysis screen puts the 3D model, plaque cross-section and FFRct values side by side, which shows real workflow thought.
Roadmap, FFRct, Plaque and PCI Navigator unify under one platform, easing the ramp from first read to ongoing management.
A dedicated mobile app exists for physicians but appears read-focused, not a full clinical workflow.
Contact-sales only, no trial: onboarding is institutional, via Heartflow University and support staff.
625+ peer-reviewed publications and CMS reimbursement backing signal a validated, mature clinical product.
Hospitals and imaging centers already running CCTA programs that want AI-assisted plaque and flow analysis in one platform.
You want to self-serve trial a tool before committing an institution to a sales conversation.
650,000 patients treated and 625 papers cited — that's not a startup pitch deck, that's a track record.
“HeartFlow has the evidence density most AI-healthcare vendors fake. Cleerly and Elucid are chasing the same CCTA workflow, but HeartFlow got there first and got paid for it.”
No pricing page. Category norm for B2B medical device software — CMS reimbursement codes exist, but list price doesn't. That's fine here, not a red flag, because the reimbursement structure (99.5% of US insurance lives, 235 million patients covered per their numbers) is the actual moat, not a marketing line.
1,800 institutions. 650,000 patients. 625 peer-reviewed publications. That's a lot of receipts for a category where I'd normally expect vaporware claims about 'transforming' something. The tagline says 'decisive coronary care' — aspirational, sure, but backed by ACC/AHA guideline citations, not just adjectives.
Exit portability is the real question mark. This isn't a SaaS tool you swap out — it's embedded in a hospital's CCTA workflow, tied to reimbursement codes and clinician training. Ripping it out after 18 months means retraining readers and possibly losing the insurance pathway. Cleerly is the obvious alternative if HeartFlow's support ever slips.
Cleerly and Elucid do similar plaque/FFR analysis; HeartFlow's edge is scale and guideline endorsement, not unique tech.
Deeply embedded in CCTA clinical workflow and reimbursement coding — no stated migration path off the platform.
CMS-approved reimbursement and NICE recommendation signal durable institutional buy-in, and a 2025 Nasdaq listing (HTFL) puts its financials in public filings.
Claims are grounded in reimbursement data and 625 cited publications, not just superlatives.
650,000 patients across 1,800 institutions matches a mature, adopted-category pattern, not a launch-stage one.
Hospitals and imaging centers building or scaling a CCTA-based cardiology program.
Avoid if you need transparent self-serve pricing before engaging sales.
Common questions answered by our AI research team
Roadmap Analysis efficiently reads every CCTA scan for fast, accurate, and early detection of coronary artery disease, delivering consistent results across different readers.
FFRCT Analysis assesses blood flow anywhere in the coronary tree, helping clinicians determine whether a patient would benefit from revascularization.
Plaque Analysis quantifies and characterizes plaque within the coronary arteries, informing risk assessment and helping clinicians manage coronary artery disease over time.
Heartflow requires a Coronary CT Angiography (CCTA) scan, which it processes into a dynamic, personalized 3D model of the heart assessing both anatomy and physiology.
Yes. Heartflow Plaque Analysis is supported by scientific statements from the American College of Cardiology and American Heart Association, and late-breaking AHA 2025 data reinforced it as the most clinically validated framework for coronary risk stratification.
Who HeartFlow competes with, and how each one differs
The closest direct rival: Cleerly sells an AI-enabled CCTA read (Cleerly Plaque Analysis, Cleerly ISCHEMIA, Cleerly COMPARE) and markets ISCHEMIA head-to-head against FFR-CT using CREDENCE and PACIFIC trial data. Heartflow's own 10-K names Cleerly first among AI-CCTA competitors; Cleerly is still venture-backed (a $106M round from Insight Partners in December 2024), while Heartflow is Nasdaq-listed with $176.0M of 2025 revenue.
Aidoc sells a broad enterprise clinical-AI platform (aiOS) carrying the largest portfolio of FDA-cleared triage algorithms across radiology, neurovascular, vascular and cardiology, including a coronary artery disease solution. It competes for the same hospital imaging-AI budget but monetises platform-wide deployment and incidental-finding capture, not Heartflow's single CPT-reimbursed, pay-per-click diagnostic test.
Nanox.AI (the former Zebra Medical, acquired November 2021) runs HealthCCSng, an FDA-cleared cardiac tool that mines routine chest and abdomen CT scans to flag patients at high risk of coronary artery disease. That is opportunistic population screening on scans already taken, whereas Heartflow analyses a dedicated coronary CT angiogram to return an FFR-CT and plaque report; Nanox also sells imaging hardware, which Heartflow does not.
Viz.ai is an AI care-coordination platform layered on hospital imaging, with a Cardio Suite covering hypertrophic cardiomyopathy, acute coronary syndrome and cardiac amyloidosis alongside its neuro and vascular suites. It overlaps with Heartflow on the cardiology AI budget and CT ingest, but sells acute detection and care-team activation rather than a reimbursed CCTA-derived diagnostic analysis.
HeartFlow is a medical technology company based in Mountain View, California, that develops non-invasive imaging software to diagnose coronary artery disease.
